DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Loeys-Dietz syndrome 1 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLoeys-Dietz syndrome 1 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for loeys-dietz syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
transforming growth factor beta receptor 2 (TGFBR2) — TGFBR2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-methoxypyridin-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5QIN · 1.57 Å · ligand N-{4-[3-(6-methoxypyridin-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl]pyridin-2-yl}acetamide (J2V). Experimental structure, not a prediction.
What the evidence adds up to
In a 2014 study of 23 Loeys-Dietz syndrome patients, including six with novel TGF-β receptor mutations, gene expression profiling of outgrowth endothelial cells showed altered expression of BMP2, BMP4, and BMPR1A. The BMP antagonist Gremlin-1 was the most prominently up-regulated gene, confirmed at the protein level in endothelial cells and smooth muscle cells of the arterial media. Plasma Gremlin-1 levels were significantly elevated in LDS patients compared to healthy controls. The authors proposed these findings could lead to new diagnostic serological methods for early disease detection, but no therapeutic intervention was tested.
A 2014 case report described anaesthetic management for a Loeys-Dietz syndrome type I patient undergoing laparotomy for a suspected twisted ovarian cyst. The report noted LDS is caused by mutations in TGFBR1, TGFBR2, TGFB2, or SMAD3, with type I accounting for more than 75% of cases. No drug treatment or outcome data beyond the surgical procedure were provided.
A 2022 report followed a 27-year-old woman with LDS over a 10-year surgical course, documenting ectopic arterial enlargement through serial CT imaging and pathology findings from two surgeries. The report described temporal changes in arterial dilation but offered no pharmacological intervention or quantitative survival data.
No drug has been tested in a controlled trial for Loeys-Dietz syndrome. What is missing is any randomised clinical trial, a defined patient stratification strategy, and funding for such studies. The Gremlin-1 finding remains a biomarker observation without a linked therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2014 · 18 citations · open access
Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
AbstractBACKGROUNDS: The Loeys-Dietz syndrome (LDS) is an inherited connective tissue disorder caused by mutations in the transforming growth factor β (TGF-β) receptors TGFBR1 or TGFBR2. Most patients with LDS develop severe aortic aneurysms resulting in early need of surgical intervention. In order to gain further insight into the pathophysiology of the disorder, we investigated circulating outgrowth endothelial cells (OEC) from the peripheral blood of LDS patients from a cohort of 23 patients including 6 patients with novel TGF-β receptor mutations. METHODS AND RESULTS: We performed gene expression profiling of OECs using microarray analysis followed by quantitative PCR for verification of gene expression. Compared to OECs of age- and sex-matched healthy controls, OECs isolated from three LDS patients displayed altered expression of several genes belonging to the TGF-β pathway, especially those affecting bone morphogenic protein (BMP) signalling including BMP2, BMP4 and BMPR1A. Gene expression of BMP antagonist Gremlin-1 (GREM1) showed the most prominent up-regulation. This increase was confirmed at the protein level by immunoblotting of LDS-OECs. In immunohistochemistry, abundant Gremlin-1 protein expression could be verified in endothelial cells as well as smooth muscle cells within the arterial media. Furthermore, Gremlin-1 plasma levels of LDS patients were significantly elevated compared to healthy control subjects. CONCLUSIONS: These findings open new avenues in the understanding of the pathogenesis of Loeys-Dietz syndrome and the development of new diagnostic serological methods for early disease detection.
Journal of Evolution of Medical and Dental Sciences · 2014 · 0 citations · open access
ANAESTHETIC MANAGEMENT FOR A RARE CASE OF LOEYS - DIETZ SYNDROME FOR LAPAROTOMY
AbstractLoeys-Dietz syndrome (LDS) is an autosomally dominant connective tissue disorder characterised by vascular and skeletal manifestations. It is caused by mutations in the TGFBR1, TGFBR2, TGFB2 or SMAD3 genes. There are four types of which type I is the most common accounting for more than 75% of the cases. Here we report the anaesthetic management of a case of LDS type I who presented with abdominal pain with suspected twisted ovarian cyst for laparotomy.
Research Square · 2022 · 0 citations · open access
Ectopic Vasodilation of a young woman with Loeys-Dietz syndrome in 10 years
AbstractAbstract We report the 10-year surgical course of a 27-year-old young woman who underwent two surgeries s after being diagnosed with Loeys-Dietz syndrome (LDS). As previously reported, this case showed ectopic arterial enlargement, and we can follow its temporal changes over a 10-year period. We described computed tomography (CT) changes over time and the appearance and pathology findings in surgery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
